{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:18:17Z","timestamp":1762550297755,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001296","name":"PKD Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001296","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.cgh.2016.03.008","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T21:00:14Z","timestamp":1457643614000},"page":"1031-1034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Polycystic Liver Disease: The Benefits of Targeting cAMP"],"prefix":"10.1016","volume":"14","author":[{"given":"Nicholas F.","family":"Larusso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana V.","family":"Masyuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie C.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2016.03.008_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","article-title":"Diagnosis and management of polycystic liver disease","volume":"10","author":"Gevers","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.03.008_bib2","article-title":"Therapeutic targets in polycystic liver disease","author":"Masyuk","year":"2015","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.cgh.2016.03.008_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/hep.1840110406","article-title":"Functional similarities of hepatic cystic and biliary epithelium: studies of fluid constituents and in\u00a0vivo secretion in response to secretin","volume":"11","author":"Everson","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.03.008_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hep.22636","article-title":"The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD)","volume":"49","author":"Banales","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.03.008_bib5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2353\/ajpath.2008.080125","article-title":"Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease","volume":"173","author":"Banales","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cgh.2016.03.008_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2016.03.008_bib7","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.03.008_bib8","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/gut.2008.155721","article-title":"Somatostatin analogues reduce liver volume in polycystic liver disease","volume":"57","author":"van Keimpema","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.03.008_bib9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MOG.0b013e328343433f","article-title":"Somatostatin analogues for treatment of polycystic liver disease","volume":"27","author":"Gevers","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.cgh.2016.03.008_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11255-010-9748-1","article-title":"Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease","volume":"43","author":"Peces","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.cgh.2016.03.008_bib11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1478-3231.2009.02123.x","article-title":"Effect of octreotide on polycystic liver volume","volume":"30","author":"van Keimpema","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2016.03.008_bib12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","article-title":"Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease.","volume":"14","author":"Pisani","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.03.008_bib13","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.03.008_bib14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2016.03.008_bib15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cgh.2016.03.008_bib16","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cgh.2016.03.008_bib17","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cgh.2016.03.008_bib18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.mayocp.2015.05.011","article-title":"Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease","volume":"90","author":"Hogan","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cgh.2016.03.008_bib19","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.cgh.2015.05.039","article-title":"Lanreotide reduces liver volume, but might not improve muscle wasting or weight loss, in patients with symptomatic polycystic liver disease","volume":"13","author":"Temmerman","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.03.008_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","article-title":"Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial","volume":"59","author":"Chrispijn","year":"2013","journal-title":"J\u00a0Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356516002469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356516002469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:12:35Z","timestamp":1762549955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356516002469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1542356516002469"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2016.03.008","relation":{},"ISSN":["1542-3565"],"issn-type":[{"type":"print","value":"1542-3565"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polycystic Liver Disease: The Benefits of Targeting cAMP","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2016.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2015.12.049","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute","name":"copyright","label":"Copyright"}]}}